☰

Innovative Medicines Canada
Code of Ethical Practices

Table of Contents Favourites News Events

Language:
- EN
- FR

?

Search for:

Introduction
1 - Guiding Principles
2 - Privacy of Patient Information
3 - Transparency
4 - Members’ Employees
5 - Scientific Exchanges
6 - Business Meetings and Discussions
7 - Retaining the Services of a Stakeholder
8 - Consultant Meetings
9 - Learning Programs for Health Care Professionals
10 - Conferences and Congresses
11 - Displays
12 - Provision of Funding
13 - Collaborations and Partnerships
14 - Loan of Medical Equipment
15 - Patient Support Programs and Medical Practice Activities
16 - Service-Oriented Items
17 - Clinical Evaluation Packages (“Samples”)
18 - Market Research
19 - Post Registration Clinical Studies
20 - Enforcement
ANNEX A - Innovative Medicines Canada Guidelines for Transparency in Stakeholder Funding

My Favourites

Clear favorites

News

IMC Statement on New Federal Government Task Force
MEET THE EXPERTS: JOE FARAGO
Innovative Medicines Canada responds to release of Patented Medicine Prices Review Board’s (PMPRB) final Guidelines
PMPRB research fact checker
Innovative Medicines Canada commits to support Canada’s economic recovery while protecting Canadians’ health and well-being

Events

Sorry, can not connect to the events feed.

No items

2

2Privacy of Patient InformationAdd to favorites

2.1Privacy of Patient Information

Members must abide by federal/provincial/territorial laws and regulations pertaining to the privacy of patient information.{{1}}

Annotations (x returns to text)

Personal Information Protection and Electronic Documents Act, S.C. 2000, c. 5 (PIPEDA) and Canadian Anti-Spam Legislation.x

X

Questions about this App? Please send us an email at
code@imc-mnc.ca.